Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis

Y.H. Lee,S.-C. Bae

Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis

2018

Y.H. Lee
S.-C. Bae

Objective This study aimed to assess the relative efficacy and safety of once-daily baricitinib 2 mg and 4 mg administration in patients with active rheumatoid arthritis (RA).

Keywords:

Physical therapy
Rheumatoid arthritis
Baricitinib
Medicine
relative efficacy
Meta-analysis
Rheumatology
Randomized controlled trial
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations